Mostrar el registro sencillo del ítem

dc.contributor.authorMartin-Lorenzo, Marta
dc.contributor.authorMartinez, Paula J
dc.contributor.authorBaldan-Martin, Montserrat
dc.contributor.authorLopez, Juan Antonio 
dc.contributor.authorMinguez, Pablo
dc.contributor.authorSantiago-Hernandez, Aranzazu
dc.contributor.authorVazquez, Jesus 
dc.contributor.authorSegura, Julian
dc.contributor.authorRuiz-Hurtado, Gema
dc.contributor.authorVivanco, Fernando
dc.contributor.authorBarderas, Maria G
dc.contributor.authorRuilope, Luis M
dc.contributor.authorAlvarez-Llamas, Gloria
dc.date.accessioned2019-03-18T10:35:47Z
dc.date.available2019-03-18T10:35:47Z
dc.date.issued2019-04
dc.identifier.citationHypertension. 2019 Apr;73(4):794-802es_ES
dc.identifier.issn0194-911Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/7350
dc.description.abstractResistant hypertension prevalence is progressively increasing, and prolonged exposure to suboptimal blood pressure control results in higher cardiovascular risk and end-organ damage. Among various antihypertensive agents, spironolactone seems the most effective choice to treat resistant hypertension once triple therapy including a diuretic fails. However success in blood pressure control is not guaranteed, adverse effects are not negligible, and no clinical tools are available to predict patient's response. Complementary to our previous study of resistant hypertension metabolism, here we investigated urinary proteome changes with potential capacity to predict response to spironolactone. Twenty-nine resistant hypertensives were included. A prospective study was conducted and basal urine was collected before spironolactone administration. Patients were classified in responders or nonresponders in terms of blood pressure control. Protein quantitation was performed by liquid chromatography-mass spectrometry; ELISA and target mass spectrometry analysis were performed for confirmation. Among 3310 identified proteins, HP (haptoglobin) and HPR (haptoglobin-related protein) showed the most significant variations, with increased levels in nonresponders compared with responders before drug administration (variation rate, 5.98 and 7.83, respectively). Protein-coordinated responses were also evaluated by functional enrichment analysis, finding oxidative stress, chronic inflammatory response, blood coagulation, complement activation, and regulation of focal adhesions as physiopathological mechanisms in resistant hypertension. In conclusion, protein changes able to predict patients' response to spironolactone in basal urine were here identified for the first time. These data, once further confirmed, will support clinical decisions on patients' management while contributing to optimize the rate of control of resistant hypertensives with spironolactone.es_ES
dc.description.sponsorshipThis work was supported by grants from the Instituto de Salud Carlos III co-supported by FEDER grants (PI14/01650, PI14/01917, PI14/01841, PI16/01334, IF08/3667-1, FI12/00126, CPII15/00027, CP15/00129, CP16/00116, PT13/0001/0013, PRB3 (IPT17/0019 ISCIIIS-GEFI/ERDF), REDinREN (RD12/0021/0001 and RD16/0009)) Fundación SENEFRO and Fundación Conchita Rábago de Jiménez Díaz. These results are lined up with the Spanish initiative on the Human Proteome Project.es_ES
dc.language.isoenges_ES
dc.type.hasVersionSMURes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectblood pressurees_ES
dc.subjecthaptoglobines_ES
dc.subjecthumanes_ES
dc.subjectproteomicses_ES
dc.subjectresistant hypertensiones_ES
dc.subjectspironolactonees_ES
dc.titleUrine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertensiones_ES
dc.typejournal articlees_ES
dc.rights.licenseAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.identifier.pubmedID30712426es_ES
dc.format.volume73es_ES
dc.format.number4es_ES
dc.format.page794-802es_ES
dc.identifier.doi10.1161/HYPERTENSIONAHA.118.12242es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderUnión Europea. Fondo Europeo de Desarrollo Regional (FEDER/ERDF) 
dc.contributor.funderFundación Conchita Rábago de Jiménez Díaz 
dc.contributor.funderFundación SENEFRO 
dc.description.peerreviewedes_ES
dc.identifier.e-issn1524-4563es_ES
dc.relation.publisherversionhttps://doi.org/10.1161/HYPERTENSIONAHA.118.12242es_ES
dc.identifier.journalHypertension (Dallas, Tex. : 1979)es_ES
dc.repisalud.orgCNICCNIC::Unidades técnicas::Proteómica / Metabolómicaes_ES
dc.repisalud.orgCNICCNIC::Grupos de investigación::Proteómica cardiovasculares_ES
dc.repisalud.institucionCNICes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01650es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01917es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI14/01841es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PI16/01334es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/IF08/3667-1es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FI12/00126es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CPII15/00027es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP15/00129es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/CP16/00116es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PT13/0001/0013es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD12/0021/0001es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/RD16/0009es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 Internacional